Intrust Bank NA Invests $383,000 in argenx SE (NASDAQ:ARGX)

Intrust Bank NA acquired a new stake in shares of argenx SE (NASDAQ:ARGX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 623 shares of the company’s stock, valued at approximately $383,000.

Other hedge funds have also made changes to their positions in the company. BIT Capital GmbH raised its holdings in argenx by 22.1% in the 4th quarter. BIT Capital GmbH now owns 4,032 shares of the company’s stock valued at $2,480,000 after acquiring an additional 731 shares in the last quarter. EFG Asset Management North America Corp. lifted its position in argenx by 3.1% in the fourth quarter. EFG Asset Management North America Corp. now owns 14,524 shares of the company’s stock worth $8,942,000 after purchasing an additional 440 shares during the period. LPL Financial LLC boosted its stake in argenx by 113.4% during the fourth quarter. LPL Financial LLC now owns 16,317 shares of the company’s stock worth $10,035,000 after buying an additional 8,671 shares in the last quarter. Virtu Financial LLC bought a new stake in argenx in the 4th quarter valued at $728,000. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in shares of argenx by 78.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock valued at $46,000 after buying an additional 33 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ARGX shares. Oppenheimer lifted their target price on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Truist Financial reiterated a “buy” rating and issued a $700.00 price objective (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Piper Sandler raised their target price on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. Guggenheim upped their price target on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Finally, Robert W. Baird lifted their price objective on argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a report on Tuesday, March 4th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and an average target price of $687.00.

argenx Stock Down 0.7 %

ARGX stock opened at $589.15 on Monday. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21. The company has a market cap of $35.80 billion, a P/E ratio of -669.49 and a beta of 0.59. The business has a fifty day moving average of $628.26 and a 200-day moving average of $602.12.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities research analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.